Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422198 · ClinicalTrials.gov registry record · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
A Phase 3 study of Endometrial Serous Adenocarcinoma and Endometrial Clear Cell Adenocarcinoma, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 188
- Enrollment target
- 5
- Study locations
NCT03422198 is a Phase 3 study of Endometrial Serous Adenocarcinoma and Endometrial Clear Cell Adenocarcinoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 188 participants, below the 286-participant average among 12 other Endometrial Serous Adenocarcinoma trials with a reported enrollment target (34% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03422198, a Phase 3 study of Endometrial Serous Adenocarcinoma and Endometrial Clear Cell Adenocarcinoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 188 participants
- Enrollment target
- 5
- Study locations
Study Summary
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells. After completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.
Conditions Studied
Interventions
- RADIATION Vaginal Cuff Brachytherapy
- RADIATION Short course vaginal cuff brachytherapy
Study Locations (5)
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
- Intermountain Medical Center / LDS Hospital - Salt Lake City
California
- Stanford Cancer Center - Palo Alto
Illinois
- Loyola University Medical Center - Maywood
Texas
- MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03422198
The ClinicalTrials.gov registry entry for NCT03422198 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 12 other Endometrial Serous Adenocarcinoma trials with a reported enrollment target (34% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Endometrial Serous Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Vaginal Cuff Brachytherapy is the first listed.
NCT03422198 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Utah, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT03422198 about?
NCT03422198 is a clinical study titled "Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer". This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation th...
What is the current status of trial NCT03422198?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 188 participants. The study started on 2018-02-02. Estimated completion is 2029-10-31.
What conditions does trial NCT03422198 study?
This clinical trial studies the following conditions: Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer.
What interventions are being tested in trial NCT03422198?
The interventions under investigation include: Vaginal Cuff Brachytherapy (RADIATION), Short course vaginal cuff brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT03422198?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03422198 being conducted?
This trial has 5 study locations across California, Illinois, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Serous Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RECRUITING · Phase 3
-
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
RECRUITING
-
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
ACTIVE NOT RECRUITING · NA
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Endometrial Serous Adenocarcinoma
All registered trials for this condition
Endometrial Clear Cell Adenocarcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.